Microcap Ledger Kyverna Therapeutics, Inc. $KYTX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Emeryville, CA
- Fiscal year end
- December 31
- Shares outstanding
- 61,843,444 [10-Q 2026-08-11]
What the company doesAI summary of filing
Kyverna Therapeutics is a late-stage clinical biopharmaceutical company developing autologous CAR T-cell therapies for autoimmune diseases. The company's lead product candidate, mivocabtagene autoleucel (miv-cel), is an anti-CD19 CAR T therapy currently in late-stage clinical trials for stiff person syndrome and generalized myasthenia gravis, with additional investigator-initiated trials underway in progressive multiple sclerosis, rheumatoid arthritis, lupus nephritis, and systemic sclerosis. Kyverna is pre-revenue and plans to file a biologics license application for stiff person syndrome in the first half of 2026, with cash runway projected into 2028. [10-K 2026-03-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$78.05M | −$81.90M | $31.81M | [10-Q 2026-08-11] |
| FY ended Dec 2025 | — | −$161.31M | −$153.71M | $124.09M | [10-K 2026-03-26] |
| FY ended Dec 2024 | — | −$127.48M | −$114.25M | $96.62M | [10-K 2026-03-26] |
- Quarterly cash burn
- −$40.95M
- Cash runway Estimate
- ~2.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-31 | 43,171,612 | [10-Q 2024-11-13] |
| 2025-03-01 | 43,214,918 | [10-K 2025-03-27] |
| 2025-05-01 | 43,218,873 | [10-Q 2025-05-13] |
| 2025-08-04 | 43,245,667 | [10-Q 2025-08-12] |
| 2025-10-31 | 43,796,170 | [10-Q 2025-11-12] |
| 2026-03-01 | 60,439,893 | [10-K 2026-03-26] |
| 2026-05-01 | 60,795,212 | [10-Q 2026-05-12] |
| 2026-08-03 | 61,843,444 | [10-Q 2026-08-11] |
- Shelf registration
- S-3 filed 2026-03-26; declared effective 2026-04-02 [S-3 2026-03-26]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-05-27 | Clark Ian T | grant | 5,093 | — | [4 2026-05-29] |
| 2026-05-27 | Cohen Fred E | grant | 5,093 | — | [4 2026-05-29] |
| 2026-05-27 | Seidenberg Beth C | grant | 5,093 | — | [4 2026-05-29] |
| 2026-05-27 | Shaw Christi | other | 4,194 | $8.59 | [4 2026-05-29] |
| 2026-05-27 | Aktar Mert | grant | 5,093 | — | [4 2026-05-29] |
| 2026-03-13 | Grasso Marc | grant | 10,000 | — | [4 2026-03-17] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-24 | 8-K | Regulation FD disclosure |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-11 | 10-Q | Quarterly report |
| 2026-08-11 | 8-K | Results of operations |
| 2026-07-29 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-27 | 8-K | Material agreement entered; Regulation FD disclosure |
| 2026-07-09 | 8-K | Material agreement entered |
| 2026-06-02 | 8-K | Shareholder vote results |
| 2026-05-18 | 8-K | Director or officer change; Other events |
| 2026-05-12 | 10-Q | Quarterly report |
| 2026-05-12 | 8-K | Results of operations |
| 2026-05-04 | 8-K | Other events |
Alerts for $KYTX
Email me when Kyverna Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.